Biomanufacturing the future
Transforming peptide drug manufacturing.
rBIO is developing a proprietary manufacturing process and licensing platform designed to improve the economics of peptide drug production, beginning with insulin.
20L
Pilot work completed
✓
Exploratory animal study completed
1,000L
Next planned scale-up
Global
Licensing potential
The problem
Complex manufacturing drives high drug prices.
Diabetes has reached epidemic levels, yet insulin cost and supply remain major global challenges. A key driver is the complexity, cost, and limited scalability of peptide-drug manufacturing.
rBIO is focused on solving the manufacturing problem behind drug pricing.
01
Improve efficiency
Increase production output through proprietary process innovation.
02
Reduce complexity
Create a clearer path from process development to commercial scale.
03
Stabilize supply
Enable qualified regional and strategic manufacturing partners.
04
Expand access
Improve the economics of essential peptide drug production.
Lead program
R-biolin
rBIO is applying its proprietary manufacturing process first to insulin, one of the world’s most widely used peptide drugs.
- Program focus Insulin
- Model Licensing-first
- Next milestone 1,000L scale-up
Platform
A proprietary process built for scale.
Our platform combines proprietary process IP with deep biomanufacturing know-how to improve peptide-drug production output.
Development roadmap
From proof to process-ready licensing.
Completed
20L pilot
Early process development milestone.
Completed
Exploratory study
Animal safety and efficacy work.
Next
1,000L scale-up
Planned larger-scale validation.
Target
Production ready
Prepared for qualified licensees.
Licensing model
Designed for faster global adoption.
A capital-efficient path to scale, partner-driven commercialization, and broader global access.
Validate
Complete scale-up and demonstrate process performance.
Transfer
License the proprietary process to qualified partners.
Scale
Support regional and global manufacturing adoption.
News & media
Following rBIO’s progress.
